Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q424940> ?p ?o }
Showing triples 1 to 100 of
100
with 100 triples per page.
- Q424940 subject Q10078446.
- Q424940 subject Q52376.
- Q424940 subject Q7482753.
- Q424940 subject Q8462603.
- Q424940 subject Q8965786.
- Q424940 abstract "Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."A United States patent application was submitted on 30 June 1989, for Avelox (moxifloxacin hydrochloride). In 1999 Avelox was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.Avelox (moxifloxacin) was launched in the United States in 1999 and is marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer's partner Merck.In 2011, the FDA added two box warnings for this drug in reference to spontaneous tendon ruptures and the fact that moxifloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and life-threatening breathing problems.".
- Q424940 atcPrefix "J01".
- Q424940 atcSuffix "MA14".
- Q424940 bioavailability "86.0".
- Q424940 casNumber "354812-41-2".
- Q424940 drugbank "DB00218".
- Q424940 fdaUniiCode "U188XYD42P".
- Q424940 iupacName "1-Cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid".
- Q424940 pubchem "152946".
- Q424940 thumbnail Moxifloxacin_Structural_Formulae_V.1.svg?width=300.
- Q424940 wikiPageWikiLink Q10078446.
- Q424940 wikiPageWikiLink Q1050046.
- Q424940 wikiPageWikiLink Q1053948.
- Q424940 wikiPageWikiLink Q1141979.
- Q424940 wikiPageWikiLink Q1144385.
- Q424940 wikiPageWikiLink Q11995.
- Q424940 wikiPageWikiLink Q12074763.
- Q424940 wikiPageWikiLink Q12204.
- Q424940 wikiPageWikiLink Q129104.
- Q424940 wikiPageWikiLink Q131742.
- Q424940 wikiPageWikiLink Q131854.
- Q424940 wikiPageWikiLink Q131915.
- Q424940 wikiPageWikiLink Q134281.
- Q424940 wikiPageWikiLink Q137786.
- Q424940 wikiPageWikiLink Q144085.
- Q424940 wikiPageWikiLink Q158013.
- Q424940 wikiPageWikiLink Q161437.
- Q424940 wikiPageWikiLink Q1625433.
- Q424940 wikiPageWikiLink Q167844.
- Q424940 wikiPageWikiLink Q172290.
- Q424940 wikiPageWikiLink Q188121.
- Q424940 wikiPageWikiLink Q188724.
- Q424940 wikiPageWikiLink Q189790.
- Q424940 wikiPageWikiLink Q194309.
- Q424940 wikiPageWikiLink Q194322.
- Q424940 wikiPageWikiLink Q2046669.
- Q424940 wikiPageWikiLink Q204711.
- Q424940 wikiPageWikiLink Q210420.
- Q424940 wikiPageWikiLink Q210975.
- Q424940 wikiPageWikiLink Q221179.
- Q424940 wikiPageWikiLink Q25419.
- Q424940 wikiPageWikiLink Q256602.
- Q424940 wikiPageWikiLink Q273554.
- Q424940 wikiPageWikiLink Q274493.
- Q424940 wikiPageWikiLink Q280027.
- Q424940 wikiPageWikiLink Q310543.
- Q424940 wikiPageWikiLink Q36496.
- Q424940 wikiPageWikiLink Q407431.
- Q424940 wikiPageWikiLink Q407693.
- Q424940 wikiPageWikiLink Q407828.
- Q424940 wikiPageWikiLink Q41571.
- Q424940 wikiPageWikiLink Q420548.
- Q424940 wikiPageWikiLink Q423673.
- Q424940 wikiPageWikiLink Q424193.
- Q424940 wikiPageWikiLink Q426549.
- Q424940 wikiPageWikiLink Q467717.
- Q424940 wikiPageWikiLink Q47273.
- Q424940 wikiPageWikiLink Q48143.
- Q424940 wikiPageWikiLink Q4971815.
- Q424940 wikiPageWikiLink Q499574.
- Q424940 wikiPageWikiLink Q52376.
- Q424940 wikiPageWikiLink Q614156.
- Q424940 wikiPageWikiLink Q621636.
- Q424940 wikiPageWikiLink Q632006.
- Q424940 wikiPageWikiLink Q640448.
- Q424940 wikiPageWikiLink Q660.
- Q424940 wikiPageWikiLink Q663.
- Q424940 wikiPageWikiLink Q684825.
- Q424940 wikiPageWikiLink Q7482753.
- Q424940 wikiPageWikiLink Q754447.
- Q424940 wikiPageWikiLink Q82504.
- Q424940 wikiPageWikiLink Q8285.
- Q424940 wikiPageWikiLink Q8462603.
- Q424940 wikiPageWikiLink Q846309.
- Q424940 wikiPageWikiLink Q857288.
- Q424940 wikiPageWikiLink Q876887.
- Q424940 wikiPageWikiLink Q8965786.
- Q424940 wikiPageWikiLink Q945238.
- Q424940 atcPrefix "J01".
- Q424940 atcSuffix "MA14".
- Q424940 bioavailability "86".
- Q424940 casNumber "354812".
- Q424940 drugbank "DB00218".
- Q424940 iupacName "1".
- Q424940 pubchem "152946".
- Q424940 unii "U188XYD42P".
- Q424940 type ChemicalSubstance.
- Q424940 type Drug.
- Q424940 type ChemicalObject.
- Q424940 type Thing.
- Q424940 type Q8386.
- Q424940 comment "Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye).".
- Q424940 label "Moxifloxacin".
- Q424940 seeAlso Q426549.
- Q424940 depiction Moxifloxacin_Structural_Formulae_V.1.svg.